Trualt Bioenergy IPO has entered its final day of subscription today. The bidding window for public subscription will close today, September 29, 2025. The allotment process for the IPO is expected to be finalised on September 30, 2025, and the company’s shares will be listed on both NSE and BSE. The tentative listing date for Trualt Bioenergy's IPO is set for October 3, 2025.
[September 29, 2025, 10:51 AM]
On Day 3, the Trualt Bioenergy IPO saw a subscription of 3.13 times, according to NSE data. The IPO was subscribed 2.10 times in the Retail Individual Investors (RII) category, 8.50 times in the Non-Institutional Investors (NII) category and 0.90 times in the Qualified Institutional Buyers (QIBs) category.
Trualt Bioenergy IPO is a bookbuilding of ₹839.28 crores. The issue is a combination of fresh issue of 1.51 crore shares aggregating to ₹750.00 crores and offer for sale (OFS) of 0.18 crore shares aggregating to ₹89.28 crores. The issue price band is set at ₹472 to ₹496 per share. The minimum lot size for an application is 30, and the minimum amount required for a retail investor is ₹14,160 (30 shares).
DAM Capital Advisors Limited and SBI Capital Markets Limited are the book-running lead managers, while Bigshare Services Private Limited serves as the registrar for the IPO.
Check out newly Listed IPOs on BSE and NSE.
The Company will utilise the net proceeds from the issue for the following purposes:
Explore other Upcoming IPOs on BSE and NSE.
TruAlt Bioenergy Ltd is one of India’s prominent biofuels/ethanol producers, headquartered in Bengaluru. It operates five distilleries in Karnataka with an installed ethanol production capacity of 2,000 kilolitres per day. The company is also active in compressed biogas (CBG) production through its subsidiary.
In FY25, TruAlt generated revenue of approximately ₹1,907.7 crore, a 56% increase from FY24, with profit after tax (PAT) rising to ₹146.6 crore from ₹31.8 crore in the same period.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.